Abstract
Congenital athymia is an ultra-rare condition characterized by profound T-cell immunodeficiency. Patients who have elevated T-cell proliferative response to mitogens or oligoclonal T-cell expansion may require immunosuppressive medications to treat and/or prevent graft-vs-host disease (GVHD/autologous GVHD). We evaluated immunosuppressive therapy use in clinical trials of allogeneic processed thymus tissue-agdc.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
